reason report
bottom line decent quarter view
publish updat model account result revis
guidanc even though retail usa revenu volum growth
good disappoint divis oper incom
miss estim consensu progress
year believ win share given
s- rx growth guidanc provid op week
market competit continu heat believ becom
even challeng deliv usa retail oper
incom beat progress maintain mp
usa retail miss oper incom estim view volum
growth revenu growth usa retail healthi s- rx
volum y/i one highest growth rate
incom miss leerink/consensu
gross margin pressur usa retail due increas
specialti mix howev also believ retail market
forc lower rate exchang volum dynam
like continu becom sever progress
year manag continu invest beauti
promot though remain skeptic long-term impact
integr sound on-track within quarter acquir
store anoth decemb still expect close
store start spring cost result
annual save fye also
integr cost next year annual synergi expect
annual within year believ transact
progress expect though expect materi earn
benefit
also behind estim post retail
oper incom compar leerink/
consensu believ reimburs
environ remain headwind manag
highlight call trade remain challeng
neg surpris y/i declin oper incom
constant currenc basi retail intern divis deterior
earn divis fairli consist past year
net debt total capit
price-to-earnings lt ep growth
ep
compani inform leerink partner llc research
ep exclud acquisition-rel cost acquisition-rel amort non-recur item includ lifo adjust revenu billion
pleas refer page import disclosur price chart analyst certif
divis post oper earn compar
leerink/consensu divis miss
earn estim growth view favor
highlight procur challeng believ gener deflat
continu rate price gener product declin
wholesal europ face margin headwind
tweak estim tweak estim
due entir lower share-count
guid increas low-end rang
expect materi impact earn
manag highlight market continu integr
vertic though feel need outright acquisit
partnership suffic mani case
largest global pharmaci led retail pharmaceut wholesal
organ world walgreen us drugstor chain largest pharmaci chain
us store count industri size improv purchas power brand-nam
recognit improv store traffic overal volum health plan self-insur
employ seek reduc medic cost via restrict network believ walgreen in-stor
clinic may provid attract altern plan walgreen nation presenc
also attract mani plan view provid larg corpor broad access
view gener launch wave next sever year posit impact
bottom line walgreen balanc reward custom loyalti program help lower
print ad cost bring individu market benefit recent work increas wba
privat brand product share mix well new front-end merchandis strategi
posit impact same-stor sale profit addit walgreen recent deal allianc
boot op offer promis long-term synergi global growth
back lost share esrx mp network disput
although grow accept narrow network remain risk walgreen provid
health plan wide array servic includ infus specialti dispens lab servic
hospit partnership primari care servic case walgreen also earli
mover advantag purchas jv boot deal walgreen
pbm may advantag case make retail chain payer agnost
mani strength believ retail channel face signific challeng
includ increasingli competit environ seek creat
restrict prefer narrow network deal effort captur store traffic volum
medacorp specialist check indic retail rate reduc
case keep pressur retail gross margin
furthermor on-going gener launch believ wave
larg behind us becom increasingli difficult show gross margin expans
retail also believ transact posit busi stock howev
deterior lose share even though deal approv investor
sentiment stock name appear low lastli threat amazon enter
pharmaci servic space continu weigh stock believ
retail exposur sinc own pbm given risk
concern rate share market perform
next month expect share trade ep
would put stock price use slightli higher multipl top reflect
market overal multipl reflect transact increment volum recent
narrow restrict network deal synergi allianc boot acquisit also give
opportun drive upsid chang capit structur futur
activ believ posit win share becom extens network
vast array clinic capabl believ new manag team take step
reduc overal cost increas sale higher margin front-stor product
posit retail rate remain signific pressur brand gener price also
headwind becom aggress overal respons market
also overhang unlik abat time soon given challeng concern
rate share market perform
competit high retail pharmaci industri highli competit contract
pbm manufactur also competit walgreen compet chain
independ drug store well mail order prescript provid groceri store on-line
pharmaci pharmaceut vendor chang competit landscap
impact rx volum neg impact compani sale earn
macroeconom regulatori climat uncertainti continu econom slowdown
 would bode poorli sinc above-averag unemploy rate drive lower
level consum spend would decreas prescript drug util regulatori
environ also fair amount uncertainti time impact variou
healthcar reform provis could materi impact wba oper nation emphasi
reduc healthcar cost could also spawn reimburs pressur new way contain
healthcar cost devis implement
intern exposur execut risk walgreen merger allianc boot increas
exposur intern market increas currenc exposur regulatori risk
wba partnership uniqu approach contract distribut
compani fail execut vision accret could expect
season time cost adjust swing result front-end sale
prescript sale compon season sale also lumpi depend
holiday line calendar sever cold cough flu season
magnitud compani lifo provis also fluctuat given quarter depend
inventori level sale inflat also swing result contribut earn
miss beat
potenti amazon entri amazon may seek disrupt pharmaci market
enter retail market buy build contract pbm news topic
pose headlin risk share amazon would formid competitor mail cash
incom statement model fiscal year end august mm
sale
revenu
revenu
gross profit sg spread bp
equiti earn ab
share allianc boot associ
sale acquisit adjust
revenu
revenu
net earn attr nci
revenu
total non-gaap adjust tax
compani report leerink partner llc estim
revenu
revenu
equiti earn allianc boot
sale acquisit adjust
compani report leerink partner llc estim
incom statement model fiscal year end august mm
revenu
revenu
revenu
revenu
adjust equiti earn
elimin unalloc
sale
compani report leerink partner llc estim
incom statement model fiscal year end august mm
sale
equiti earn allianc boot
share allianc boot associ
previous held equiti interest
tax earn equiti method invest
net incom attrib non-control interest
net incom attrib walgreen
gain previous held equiti interest
increas decreas fair market valu warrant
partial releas capit loss valuat allow
loss sale busi
gain previous held equiti interest
increas decreas fair market valu warrant
partial releas capit loss valuat allow
compani report leerink partner llc estim
